Maiva Pharma secures Rs 1,000 Cr investment from Morgan Stanley and India Life Sciences Fund
India, May 2 -- Maiva Pharma, headquartered in Bengaluru and known as India's second-largest injectables Contract Development and Manufacturing Organization (CDMO) for North America, has announced a significant milestone in its growth journey.
The company has successfully raised approximately Rs 1,000 crore in primary and secondary funding from a fund managed by Morgan Stanley Private Equity Asia and India Life Sciences Fund - IV (ILSF - IV). This investment marks Maiva's first private equity fundraise and signals a significant move in the healthcare investment landscape.
The funding has been utilised to acquire a controlling stake from existing investors and to infuse primary capital into the company. Maiva Pharma plans to allocate the...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.